|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate whether dysregulation of KAI1 occurs during the progression of human prostatic cancer, protein expression, mutation, and allelic loss of KAI1 were analyzed using a tissue bank of 98 primary cancers and 32 metastases.
|
8813131 |
1996 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation of the mRNA levels obtained by Northern blot analysis with clinical parameters of the patients revealed that KAI1 mRNA levels were significantly higher (P < 0.01) in earlier tumor stages (I, II), compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present.
|
8895737 |
1996 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, KAI1 mRNA expression was similar in primary esophageal and gastric cancer samples with or without metastases.
|
9485031 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical analysis of KAI1 mRNA levels and clinical parameters of the patients revealed that KAI1 mRNA levels were significantly higher in non-metastasized tumors compared with tumors in which lymph node or distant metastases were present.
|
9699525 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a tumor metastasis suppressor gene that is capable of inhibiting the metastatic process in animals.
|
9736732 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, most of the primary HCC cells in samples with metastases showed only faint or moderate KAI1 mRNA expression predominantly in the perinuclear regions.
|
9828210 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It is suggested that KAI1 gene expression may be related to the metastases of hepatocellular carcinoma.
|
9894767 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This differential expression of the metastasis suppressor gene KAI1 in primary prostate cancers may have important prognostic implications for the development of subsequent metastases.
|
10440748 |
1999 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the KAI1 mRNA expression and the KAI1 protein level increase in an earlier tumor stage of colorectal cancer, decrease in advanced stages, and are lost in metastases.
|
10568187 |
1999 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
These results, combined with recent studies of the tumor metastasis suppressor gene KAI1 and plasminogen activator inhibitor 1 (PAI1), define a new category of molecular targets of p53 that have the potential to negatively regulate tumor invasion and/or metastasis.
|
10692390 |
2000 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of KAI-1 expression in metastatic cancer cells by phorbol esters.
|
10779634 |
2000 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a metastasis suppressor gene which is capable of inhibiting the processes of tumor metastasis without affecting tumorigenicity per se.
|
10913345 |
2000 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, tumor suppressor genes such as KAI1 are expressed at reduced levels, thereby enhancing the ability of pancreatic cells to form metastases.
|
12120231 |
2001 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased KAI1 expression significantly correlated with distant metastases (Mann-Whitney, p = 0.0001, mRNA; p = 0.033, protein), cancer-specific survival (Cox regression analysis p = 0.0002, mRNA; 0.0493, protein) and overall patient survival (p = 0.0001, mRNA).
|
12530084 |
2003 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells.
|
12955496 |
2003 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression.
|
14612520 |
2003 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer.
|
15205336 |
2004 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of CD82 and CD63 was analysed by reverse transcriptase-PCR (RT-PCR) and immunohistochemistry in benign goiter (n=12) and 75 primary thyroid carcinoma tissue specimens (PTC: 33, FTC: 24, UTC: 18) out of which 36 were non-metastasized primary tumors and 39 were metastasized tumors (regional lymph node and/or distant metastases).
|
15375577 |
2004 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, we have reported the dynamic role of a beta-catenin-reptin chromatin remodelling complex in regulating a metastasis suppressor gene KAI1 (ref.1), which is capable of inhibiting the progression of tumour metastasis.
|
16699503 |
2006 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of KAI1 has been found to be clinically associated with metastatic progression in a variety of cancers, whereas overexpression of CD82 specifically suppresses tumor metastasis in various animal models.
|
16862154 |
2006 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In both cases, we found that the delivery of either MRP-1/CD9 or KAI1/CD82 cDNA dramatically reduced the metastases to the mediastinal lymph nodes in comparison with those of LacZ gene delivery, without affecting the primary tumor growth at the implanted site.
|
17308116 |
2007 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The KAI1/CD82 protein has been documented as the tumor metastasis suppressor in many types of human cancers.
|
17560548 |
2007 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Analyses of metastases with and without KAI1 transfection in mice were different in liver and lung between controls 1.62 +/- 0.39, 0.45 +/- 0.09, pCMV-KAI 1.01 +/- 0.27, 0.33 +/- 0.09 and KAI1-Lipofectamine 0.99 +/- 0.21, 0.30 +/- 0.09 respectively (P < 0.05).
|
18286698 |
2008 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study suggests an association of decreased KAI1/CD82 expression with tumour progression, development of metastases and disease-specific death.
|
18305955 |
2008 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased level of KAI1/CD82 also results in the suppression of secondary tumour growth.
|
19224455 |
2009 |